GLP-1 Medications Guide

Evidence-based information on GLP-1 receptor agonists for weight loss and metabolic health

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that have reshaped weight loss and diabetes management. The category now includes three FDA-approved pills alongside the injectables, following the April 2026 approval of orforglipron. Our guides cover choosing between them, administration, clinical indications beyond weight, and managing side effects.

Latest approval

Orforglipron (Foundayo) — the first GLP-1 pill with no food or water restrictions

Approved by the FDA on 1 April 2026 for chronic weight management. Unlike the other oral GLP-1s, it can be taken any time of day without fasting. Phase 3 data showed up to 12.4% mean weight loss at 72 weeks, with self-pay pricing starting near $149/month.

Read the approval analysis →Full clinical review →

Oral GLP-1 Medications

Every Pill Compared

Foundayo vs Wegovy pill vs Rybelsus

Orforglipron vs Semaglutide

Efficacy, burden and cost

Wegovy Pill Review

Oral semaglutide 25 mg in depth

Beyond Weight Loss

Sleep Apnea

The first drug approved for OSA

Fatty Liver (MASH)

Histology-confirmed fibrosis benefit

Kidney Disease

Albuminuria reduction of 20-40%

Knee Osteoarthritis

NEJM evidence on pain reduction

Alcohol Use Disorder

Three randomized trials

PCOS

Weight, cycles and fertility

Safety and Side Effects

Muscle Loss

What preserves lean mass

Gastroparesis

Where normal effects end

Birth Control

The tirzepatide interaction

Hair Loss

Telogen effluvium explained

Cancer Risk

The thyroid warning

Stopping Treatment

What the regain data shows

Medication Comparisons

Best GLP-1 for Weight Loss

Comprehensive comparison of semaglutide, tirzepatide, and other GLP-1 medications with clinical trial data and efficacy outcomes.

Read guide →

Best GLP-1 Medications

Detailed analysis of all available GLP-1 receptor agonists and their applications.